Skip to main content
. 2018 Apr 24;38(11):2103–2117. doi: 10.1097/IAE.0000000000002195

Fig. 1.

Fig. 1.

Vision outcomes across trials of eyes with PEDs.9,12,13,15,16 AFL, aflibercept; ETDRS, Early Treatment Diabetic Retinopathy Study; LD, loading dose; PRN, as needed; q4w, every 4 weeks; q8w, every 8 weeks; 2q8, every 8 weeks; RBZ, ranibizumab; TR, treatment-resistant; V, vascular.